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resumo 
 
 
As células estaminais mesenquimais (MSCs) são células não-hematopoéticas, 
multipotentes, capazes de se auto-renovar e de diferenciar em diferentes tipos 
celulares. As MSCs estão presentes em tecidos mesenquimais e de tecidos 
extra embrionários, tais como a matriz do cordão umbilical/Wharton’s Jelly(WJ). 
Estes últimos constituem uma boa fonte de de MSCs, sendo estas mais naive e 
tendo um maior potencial de proliferação do que as MSCs obtidas de tecidos 
adultos, como a medula óssea, tornando as MSCs da matriz do cordão 
umbilical/Wharton’s Jelly sejam mais apelativas para uso clínico.  
As MSCs possuem a capacidade de modularem tanto o sistema imune inato 
como o adquirido e os seus efeitos são vastos, afectando todas as células do 
sistema imune. Esta capacidade é bastante vantajosa para o uso terapêutico 
destas células em doenças do sistema imunitário.  
A mecanotransducção é por definição o mecanismos pelo qual as células 
convertem estímulos mecânicos em uma resposta bioquímica e com mudanças 
na sua morfologia. Apartir destas observações colocámos a hipotese de que 
mantendo MSCs in vitro em diferentes substratos poderia influencia a sua 
capacidade imunomoduladora.  
Com este trabalho, demonstrámos que ao plaquear MSCs em diferentes 
substratos de PDMS, estas mostram uma tendência para secretar quantidades 
diferentes de vários factores soluveis analisados, relativamente a MSCs 
mantidas em cultura em plataformas convencionais (placas de cultura de células 
- TCP). Para além disto, foi também observado que MSCs plaqueadas em 
substratos de PDMS aparentavam possuir uma maior capacidade 
imunomoduladora quando comparadas com MSCs mantidas em condições 
convencionais.  
Em conjunto todos os resultados obtidos sugerem que elementos relacionados 
com a mecanotransdução parecem influenciar a capacidade imunomoduladora 
de MSCs  e a sua secreção de factores solúveis. Deste modo,  estudos futuros 
poderão elucidar os mecanismos responsáveis por estas observações, de modo 
a permitir que se possa constitutuir melhores estratégias de cultura de MSCs 
para futuro uso terapêutico dirigido a doenças do sistema imunitário.  
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abstract 
 
Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent stem cells 
capable to self-renew and differentiate along different cell lineages. MSCs can 
be found in adult tissues and extra embryonic tissues like the umbilical cord 
matrix/Wharton’s Jelly (WJ). The latter constitute a good source of MSCs, being 
more naïve and having a higher proliferative potential than MSCs from adult 
tissues like the bone marrow, turning them more appealing for clinical use.  
It is clear that MSCs modulate both innate and adaptive immune responses and 
its immunodulatory effects are wide, extending to T cells and dendritic cells, 
being therapeutically useful for treatment of immune system disorders.  
Mechanotransduction is by definition the mechanism by which cells transform 
mechanical signals translating that information into biochemical and 
morphological changes. Here, we hypothesize that by culturing WJ-MSCs on 
distinct substrates with different stiffness and biochemical composition, may 
influence the immunomodulatory capacity of the cells.  
Here, we showed that WJ-MSCs cultured on distinct PDMS substrates presented 
different secretory profiles from cells cultured on regular tissue culture 
polystyrene plates (TCP), showing higher secretion of several cytokines 
analysed. Moreover, it was also shown that WJ-MSCs cultured on PDMS 
substrates seems to possess higher immunomodulatory capabilities and to 
differentially regulate the functional compartments of T cells when compared to 
MSCs maintained on TCP. 
Taken together, our results suggest that elements of mechanotransduction seem 
to be influencing the immunomodulatory ability of MSCs, as well as their 
secretory profile. Thus, future strategies will be further explored to better 
understand these observation and to envisage new in vitro culture conditions for 
MSCs aiming at distinct therapeutic approaches, namely for immune-mediated 
disorders.   
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1. Introduction  
 
1.1. Mesenchymal Stem Cells  
 Mesenchymal Stem Cells (MSCs), or mesenchymal stromal cells1 are non-
hematopoietic multipotent adult stem cell, that can be found mostly in perivascular niches 
and are responsible for the homing of hematopoietic stem cells (HSCs)2,3. These cells are 
able to self-renew and differentiate in vitro in to different mesodermal cell types, such as 
osteocytes, adipocytes and chondrocytes, but also cardiomyocyte and neural-like  cells4,5,6, 
demonstrating a putative plasticity potential.  
Alexander Friedenstein and colleagues, in 1970, were the first to describe MSCs in 
the bone marrow (BM) as fibroblast-like precursors from the bone marrow7,8 and describe 
them as plastic-adherent, with a fibroblast-like morphology , high proliferative capacity in 
vitro and with the capacity to form fibroblast colony-forming units (CFU-Fs)7, 8,9. 
According to the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy (ISCT) there are tree minimal criteria to define human MSCs: (i) 
to be adherent to plastic in standard culture conditions; (ii) MSCs must express Cluster of 
Differentiation (CD) 105, CD73 and CD90 and lack expression of CD34 (endothelial or 
primitive hematopoietic), CD45 (leukocytes), CD14 or CD11b (monocytes and 
macrophages), CD79a or CD19 (B cell) and human leukocyte antigen (HLA-DR or HLA class 
II) surface molecules [(unless stimulated by interferon-γ (IFN-γ)]; and (iii) must differentiate 
to osteocytes, adipocytes and chondrocytes in vitro10, 11. These criteria established by the 
ISCT have standardized human MSCs isolation but may not apply completely to other 
species, like murine.  
MSCs secrete several growth factors, extracellular matrix molecules and cytokines 
that play an important role in the regulation of angiogenesis, haematopoiesis and in 
immune and inflammatory response3,12.  
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1.2. Sources and characteristics of Mesenchymal Stem Cells  
Since mesenchymal stromal/stem cells (MSCs) were first described in 1970 in the 
bone marrow (BM), it has been proven the presence of MSCs in other tissues such as 
adipose tissue, skeletal muscle, connective tissue, dental pulp, synovium, periosteum, 
spleen, lung and extra embryonic tissues like placenta, amniotic fluid (AF), umbilical cord 
blood (UCB) and umbilical cord matrix/Wharton’s jelly (UCM/WJ)2,13,14. 
Most of the knowledge concerning MSCs comes from the BM studies, which has 
been considered as one of the main sources15. However, BM-MSCs have limitations in 
terms of cell numbers (for regenerative medicine only approximately 0.001% to 0.01% of 
the cell are useful)16,17 and decrease significantly with donors age in terms of proliferation 
and differentiation capacity2,18. Moreover, the procedure to obtain these cells is invasive 
and painful19 for the patient and can be followed by risk of infection5 , bleeding and chronic 
pain15 and due to these limitations describe above, alternative MSCs sources have been 
explored.  
 Extra-embryonic tissues are a good alternative source of MSCs because they have a 
higher proliferative potential than adult MSCs and immunoprivileged characteristics. 
Moreover, they seem to be more naive than MSCs isolated from adult mesenchymal 
tissues2 and adult MSCs may be less-responsive than extra-embryonic MSCs in clinical 
applications19. MSC from different sources express embryonic stem cell markers namely 
GATA-4, Rex-1, Nanog, SSEA-120. 
 To circumvent the limitations of BM, the umbilical cord (UC) has been used as an 
alternative source of MSCs. The procedure to collect these cells is safe, non-invasive and 
simple compared to BM aspirate2 (UC is routinely discard at birth)19 and it may be stored 
cryogenically with minimal loss of potency and subsequently thawed15 due to the high 
potential clinical applications of MSCs2,21. Umbilical Cord raises no major ethical, technical 
or legal22 issues for scientific research or clinical applications2.  
MSCs from the UC exhibit a fibroblast-like morphology and share commonly the 
typical MSC immunophenotypic markers, immunogenic and immunoregulatory 
characteristics19,23 and differentiation potential similar to BM-MSCs (Table I.1)2. Thus they 
fulfil the minimal criteria proposed by ISCT for MSCs described above. Four populations of 
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MSCs can been identified in the umbilical cord: (1) Wharton’s Jelly (WJ), (2) MSCs 
surrounding the umbilical vessels , (3) umbilical cord blood (UCB) and (4) MSCs from the 
subendothelium of umbilical vein24.   
 
Table 1.1 : Surface Markers expressed by MSCs from UC and BM (Adapted from Malgieri et al., 2010) 
 
 
1.3. Umbilical Cord Matrix/Wharton’s Jelly Mesenchymal Stem Cells  
The UC is an extra-embryonic tissue that constitutes the imperative link between 
fetus and mother during pregrancy17. This tissue contain two arteries and one vein, which 
are surrounded by gelatinous connective tissue, known as the Wharton’s Jelly (WJ)16,25, and 
is covered by amniotic epithelium. This tissue was first described in 1656 by Thomas 
Wharton and the first isolation report was in 1991 by McElreavey et al.16,26 . 
The WJ is constituted by extracellular matrix proteins, namely collagens fibres, 
proteoglycans, glycosaminoglycans (hyaluronic acid is the most abundant25) and have two 
main cellular types, fibroblast-like and myofibroblast cells2,16,17. 
MSCs from WJ (MSC-WJ) can be isolated from three regions: (1) the perivascular 
regions16, (2) intervascular regions and (3) the subamnion24. There are two methods to 
isolate MSCs from WJ , enzymatic digestion and explant culture23. In both cases primary 
populations can be successfully expanded ex vivo and further differentiated and 
characterized.  
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WJ-MSCs fit the minimal criteria for described mesenchymal stem cells and in 
addition, these cells express CD200 in greatest proportions and, differently to BM-MSCs, 
CD68 (macrophage-specific antigen) and CD1412. Furthermore, the mesenchymal features 
of WJ have been confirmed by the expression of specific markers from cytoskeletal lineage, 
such as nestin27, vimentin (express mainly in mesenchymal lineage cells12) and SMA16 and 
ESC markers such as Oct-4, SOX-2, Nanog, c-Kit and SSEA4 have also been described22,28. 
 
 
Figure 1.1: Anatomical compartments within the umbilical cord. Umbilical cord contains a vein and two 
arteries surrounded by a gelatinous connective tissue, the Wharton’s Jelly.(Adapted from Troyer et al., 2007) 
  
Fetuses express high levels of HLA-G which provides protection against maternal 
immune attack and subsequent rejection29 and induces the expansion of regulatory T cells 
(Tregs)16. WJ-MSCs exhibit higher intracellular concentrations of leukocyte antigen G6 
(HLA-G6)14,21, than BM-MSCs, which suggests a role in immune tolerance during pregnancy 
by avoiding a maternal immune response against the fetus and even inducing the 
expansion of regulatory T cells29,30. 
 
1.4. Immunomodulation by MSC  
 MSCs have multi-differentiation potential and plasticity and possess unique 
immunological properties. Regardless of the source from which MSCs are isolated from, 
they have been shown to be hypo-immunogenic and have potent immunosuppressive 
activity, both in vitro and in vivo16,31. This phenomenon has been in a focus of interest since 
2002 after Bartholomew and colleagues reported the immunosuppressive capacities of 
allogeneic MSCs and demonstration of the ability of MSCs from baboons to suppress 
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lymphocyte proliferation in a mixed culture in vitro and prevent the rejection of a skin 
allograft in vivo32,33. Furthermore, other studies have demonstrated that MSCs are 
immunosuppressive both in vitro and in vivo in other animal models and human studies33. 
Therefore, immunomodulation is considered as a promising feature of MSCs populations 
for clinical application. 
The expression of major histocompability complex (MHC) on all cells of the 
organism allows the immune systems to distinguish self from non-self. The hypo-
immunogenicity of MSCs can be attributed to the lack of MHC-Class II and co-stimulatory 
ligands (CD80,CD86, CD4014,CD40-L34, B7-DC) implicated in lymphocytes activation and 
even express low amounts of MHC-Class I23,29. Nevertheless, Western blot analysis of cell 
lysates shows that cells contain intracellular deposits of class II alloantigens - despite the 
fact that of not being detectable on the cell surface. Although they can be induced to 
express MHC-Class I and II, and Fas ligand by IFN-γ treatment35, but even in these conditions 
MSCs do not stimulate immunological response34. The expression of low levels of MHC-
Class I could be a mechanism to protect MSC from alloreactive Natural Killer (NK) cell-
mediated lysis29,36. MSCs can migrate and home to organs and tissues in response to 
cytokines, chemokines, adhesion molecules and growth factors and, therein, mediate 
immunomodulatory actions37,38. These characteristics allow the use of mismatched MSCs 
in vivo and lack of T cell response in an allogeneic mixed-lymphocyte reaction in vitro39. 
These characteristics are the most intriguing aspects of MSCs biology and offer great 
therapeutic promise in areas like tissue regeneration, treatment of immune diseases, cell 
vehicles for gene therapy and enhancement of hematopoietic stem cell engraftment7.  
MSCs immunomodulation is a process involving several steps (1) MSCs 
responsiveness to inflammation and migration to the site of injury, (2) licensing/activation 
of MSCs, (3) promotion of pathogen clearance if required and (4) modulation of 
inflammation40,41. In vitro, MSCs can be activated by biologically-active metabolites of 
activated immune cells, called “priming” or “pro-inflammatory activation”, the most well 
defined mechanism until today41 namely IFN-γ in the presence of other cytokines including 
TNF, IL-1α or IL-1β33,41, mimic an inflammatory environment. IFN- γ remains the first key 
“priming” agent for MSCs suppressor function. Beyond inflammatory cytokines other 
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factors might also be involve in “licensing” this ability of MSCs, like Toll-like receptors 
(TLRs)42,43. TLRs are a family of pattern recognition receptors that recognize conserved 
structures that recognize infection or tissue damage - by the release of molecules (e.g., 
endotoxin, lipopolysaccharide –LPS-, dsRNA and heat shock proteins)44 and promote the 
activation of immune cells45. MSC are among the cells that express in their surface TLRs, 
such as TLR-3 and TLR-411,45. TLR3 and TLR4 differentially license MSC; with TLR3 “priming” 
inducing anti-inflammatory MSCs and TLR4 “priming” inducing a pro-inflammatory 
phenotype40.  
MSCs can sense local microenvironment signals and in balance with them promote 
optimal immune response, which can be either inhibitory or stimulatory depending on 
current specific state of an organism40,46,47.  
MSCs have been shown to possess a broad spectrum of immunoregulatory 
capabilities, affecting both innate immune system (DCs, NKs, monocytes and neutrophils) 
and adaptive immune system (B and T cells)48 inhibiting proliferation, reducing immune cell 
cytokine secretion and alter immune cell subtypes23 and promoting the generation of 
Tregs3,36,49 (Figure I.2).  
In vitro, the behaviour of MSCs depend on diverse factors, such as the source of the 
MSCs, the type of immune cells present in the cell culture, the state of activation and 
differentiation of the T cells and the type of stimuli used.  
 
1.4.1. Mechanisms of Immunomodulation by MSCs 
The immunomodulatory actions of MSCs are not fully understood. Several issues 
are under debate and the literature is filled with contradicting ideas, however, most  
experimental studies support a non-specific anti-proliferative action of these cells over 
immune system cells by means of paracrine effects4,43 and/or by cell-cell contact-
dependent mechanisms, which create an immunosuppressive microenvironment 
(Fig.1.2.)3,50. Some discrepancies in the literature may be due to the use of different of 
experimental designs, distinct cells used in vitro and by the individual research groups47,51.  
The cell-cell contacts haves been less investigated than the soluble factors in 
immunosuppression. In several studies transwell systems were used showing indirectly 
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that cell-cell contact is required, since MSCs-mediated effects were diminished or 
abolished when effector and target cells were separated by a membrane5.  In 2003, Tse et 
al. reported that close proximity to MSCs was important in suppressing T cell 
responsiveness and suggested that direct contact between lymphocytes and MSCs was 
more important than soluble factors in the inducing immunosuppressive function52. A 
number of contact-dependent mechanisms have been reported in MSC 
immunomodulation, namely Fas/FasL, programmed death-1/programmed death ligand-1 
(PD-1/PD-L1), galectins51, Notch signalling, expression of the adhesion molecules vascular 
cell adhesion molecule I (VCAM-I), CD72, CD5834, intracellular adhesion molecule (ICAM-I 
and ICAM-2)34,40 and integrins (alpha1, alpha2, alpha3, alpha5, alpha6, alphav, beta2, beta3 
and beta4)34.  
The paracrine effects are caused by the release of various soluble 
immunomodulators. In vivo and in vitro, various soluble immunosuppressive factors have 
been reported to be produced constitutively by MSCs or released following cross-talk with 
target cells such as interleukin (IL)-1, IL-6, IL-8, IL-1053, tumour necrosis factor stimulated 
gene 6 protein (TSG-6)54, heme oxygenase-1 (HO-1)51, indoleamine 2,3-dioxygenase (IDO) 
in humans or nitric oxide (NO) in mice55, transforming growth factor-β (TGF-β), hepatocyte 
growth factor (HGF), vascular endothelial growth factor (VEGF)56, prostaglandin E2 (PGE-
2), platelet-derived growth factor42, matrix metalloproteinases (MMPs)39, cyclooxygenase-
1 (COX-1) and COX-246 and soluble HLA-G557,58. It is clear that none of these soluble factors 
has an exclusive role and that MSC-mediated immunoregulation is a redundant systems 
that is mediated by several molecules57. In relation to the signal transduction pathways 
involved in MSCs mediated immunoregulation, various intracellular transcription factors 
have been reported. Signal transducer and activator of transcription 3 (STAT-3) factor has 
an increased activity in MSCs and antigen presenting cells (APC) upon co-culture. 
Transcription factor STAT-5 was shown to be diminished in activated T cells in the presence 
of MSCs.  Another transcription factor, nuclear factor-kappa B (NFkB), has also been 
suggested to play a role in immunomodulation by MSCs53. 
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Figure 1.2: Schematic representation of interactions between mesenchymal stem cells (MSCs) and immune 
cells of the innate and adaptive immune system. A|MSCs supress resting NK cell proliferation, reduce their 
cytotoxic potential against target cells and cytokine production in vitro. B|MSCs inhibit differentiation of 
monocytes into mature dendritic cells (iDC) and their further maturation into mature DC (mDC), skew mature 
DCs to an immature DC state. The immature DCs are susceptible to killing by activated NK cells. The effect of 
MSCs on DCs impairs the stimulatory effect of mature DCs on resting NK cells and compromises antigen 
presentation to T cells, which cannot then undergo clonal expansion. C|MSCs inhibit proliferation and 
differentiation of B cells into plasma cells, reducing antibody formation. (Adapted from (Uccelli et al. 2008) 
 
The immune regulatory mechanisms are composed by a complex interconnected 
networks that combines cytokines, signalling pathways and micro-environment, and MSCs 
may exert their effect as several levels, as further detailed below.  
   
1.4.2. The effects of MSCs on immune cells  
1.4.2.1. MSCs and T Cells  
 T lymphocytes (T cells) recognize antigens and are essential for the adaptive 
immune system, being involved in the maintenance of self-tolerance, activation of other 
lymphocytes, lysis of infected cells and interaction with cells of the innate immune 
system59. T cells are divided into two main lineages, CD4+ T helper (Th) cells that modulate 
the other immune cells and CD8+ cytotoxic T cells (CTLs) that induce death of target cells, 
both of which can be subgrouped into different effector subsets (naïve, central memory, 
effector memory and effector cells)60,61. Currently, an increasing number of studies have 
reported the inhibitory effect of MSCs over immune cells, the majority of which are focused 
on T cell but less is described concerning the effect of MSCs over distinct T cell functional 
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compartments. Data is scarce and there are some contradictory results regarding the 
influence of MSCs on the naïve-effector T cell differentiation process62. This contradictory 
data may be due to different experimental approaches.  
 The immunosuppressive effect exerted by MSCs over T cells comprises inhibition of 
T cells in terms of proliferation, activation, differentiation into effector cells and effector 
function, and by altering their cytokine profile and impairing the cytolytic activity of CD8+ 
cells62  caused by MSC-released soluble factors and cell-cell contact. This suppression may 
occur directly, or indirectly via immunomodulatory effects on antigen-presenting cells 
(APC) such as DCs, resulting in altered cytokine expression and impaired antigen 
presentation63.  
 T cells proliferation stimulated by mitogens or allogeneic cells57 is inhibit by MSCs 
by preventing their entry into the S phase of cell cycle by arresting irreversibly the G0/G1 
phase through the inhibition of cyclin D2 expression59,60, which results in the induction of 
T cell anergy61,64,65. Anergic T cells are characterized by a lack of cytokine production and 
proliferation in response to antigenic stimulation, as a result of insufficient co-stimulation 
by CD40, B7-1 and B7-2, molecules that MSC lack38,50. This anti-proliferative effect is 
associated with the survival of T cells in a state of quiescence that can be partially reversed 
by IL-2 stimulation57,60.  
 Along with the inhibitory action over T cells, there is also a decreased expression of 
the cytokine IFN-γ, TNF-α and IL-2 both in vivo and in vitro60,62,64. It has also been reported 
an increased production of IL-10 and IL-4 by Th2 cells, which indicates a shift in T cells 
phenotype, from a pro-inflammatory (IFN-γ production) state to an anti-
inflammatory/tolerant state (IL-4 production)57 and promote the generation of Tregs42,61. 
The decreased expression of this cytokines inhibit the differentiation of naïve CD8+ T cells 
into cytotoxic effector cells20. MSCs supress the cytotoxicity of CD8+ if added at the 
beginning of the mixed lymphocyte culture (MLC) but when added in the cytotoxic stage 
the cytotoxicity is not affected66. Therefore, when CD8+ T cells are activated, MSCs are not 
effective in their immunosuppressive action.  
The decrease expression of these cytokines varies within the different T cell 
compartments, showing distinct inhibitory patterns. The inhibition of IFN-γ in naïve T cells 
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is reported to be only among CD8+ T cells and no inhibitory effect is detected over naïve 
CD4+ T cells. Besides, in the central memory (CM), effector memory (EM) and effector 
compartment a more pronounced effect was observed. Concerning the inhibition of TNF-
α, CM and effector CD4+ T cells and EM CD8+ T cells were the functional compartments with 
a higher decrease of expression of this cytokine. The inhibition of IL-2 is more pronounced 
among CM, EM and effector CD4+ T cells and CM CD8+ T cells35,62,67.  
 The mechanisms used by MSCs to suppress T cells are cell-cell contact mediated by 
expression of the cell death ligand PD-L1 and by soluble factors such as PGE2, IDO, COX1 
and 2, HGF, TGF-β, HLA-G5 and others19,48. 
 
1.4.2.1.1. Regulatory T cells  
Tregs suppress the proliferation and cytokine production of T cells, mediating 
peripheral tolerance by addressing autoreactive T cells that escape thymic deletion. This 
regulatory population, may be identify by the co-expression of CD4, CD25 and the 
transcription factor FoxP3 (CD4+CD25+FOXP3+)64.  
MSCs were shown to upregulate Tregs suggesting that MSCs constitute a suitable 
niche for Tregs, playing a role in their recruitment, regulation and maintenance of 
phenotype and function. This induction has been reported to be mediated by PGE2, TGF-
β1 and by direct cell-cell contact between MSCs and CD4+T cells51. The favoured activation 
of Tregs by MSCs may represent one of the important mechanisms of the 
immunosuppressive properties of MSCS, since Tregs have a regulatory function. MSCs 
upregulate the expansion of existing Tregs but do not stimulate the formation of new 
regulatory cell from naïve T cells68. 
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1.4.2.2. MSCs and B Cells  
 Similar to the effects on T cells, the molecular mechanisms of action of MSCs on B 
cells are related to both cell-cell contact and secretion of soluble factors69. 
MSCs suppress B-cell activation, proliferation, development into plasma cells61 and 
IgG secretion (even after stimulation of B-cells) through an arrest at the G0/G1 phase of 
the cell cycle70. 
 A study from Rasmusson et al. described that MSCs downregulate the expression of 
the chemokine receptors CXCR4, CXCR5 and CCR7B and the chemotaxis to CXCL12, CXCR4 
ligand, CXCL13 and CXCR5 ligand, revealing that MSCs affect the chemotactic properties of 
B cells significantly38,50,70. 
 
1.4.2.3. MSCs and NK Cells  
 Natural Killers (NK) cells are considered the major effector cells of the innate 
immune system. NKs are mostly involved in the destruction of tumour cells and virus-
infected cells, since they kill without MHC class I restrictions through the release of perforin 
and granzyme from cytotoxic granules71,72. MSCs express low levels of MHC class I, so the 
lethality of KN cells is substantially reduced if MSCs are primed by IFN-γ, as they would be 
in an inflammatory environment73. There are two subsets of NK cells, which are CD56dim NK 
cells (cytotoxic NK cells) and CD56bright NK cells (a subset that has the capacity to produce 
abundant cytokines after activation but has a low natural cytotoxicity)3,59. 
 MSCs can strongly inhibit the proliferation of resting NK cells and alter cytokine 
release, decreasing their capacity of secreting IFN-γ, TGF-α and IL-1073. Similarly to CD8+ T 
cells, activated NK cells cannot be suppressed by MSCs, and have the ability to kill 
allogeneic MSCs. In response to IFN-γ, activating receptors of NK cells such as NKp30, 
NK44p and NKG2D60 were downregulated when in co-culture with MSCs71, which in turn 
upregulate MHC avoiding being killed by NK cells60,72.  
 There is growing evidence that soluble factors such as IDO, PGE2, TGF-β and sHLA-
G5 are involved in this immunosuppressive effect72. 
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1.4.2.4. MSCs and DC Cells 
 Dendritic cells (DC) are derived from monocytes and are specialized, phagocytic 
professional antigen presenting cells (APC) that serve as a connection between the innate 
and adaptive immune system in mammals by helping to activate T and B cells4,72.  The life 
cycle of this APC consists of an immature stage followed by a mature stage characterized 
by high efficiency in antigen uptake and processing and later on by potent antigen 
presentation61. DCs uptake antigen and during maturation and activation up-regulate 
MHCs, increase the expression of co-stimulatory molecules and migrate to secondary 
lymphoid organs and present antigen to T cells, leading to a primary adaptive immune 
response producing cytokines that affect downstream T cell effector functions, during T cell 
priming. MSCs have been shown to affect most of these processes60,74,75. 
 MSCs are able to strongly inhibit DC generation from both monocytes and CD34+ 
cell precursors73, affecting all major stages of their life cycle, differentiation, maturation 
and activation61, leading to a reduction of the expression of co-stimulatory molecules and 
debilitating the ability to stimulate naïve T cell proliferation48,65. Additionally, DCs cultured 
with MSCs have been shown to induce indirect expansion of Tregs.  
Monocytes cultured under DC-differentiating conditions in presence of MSCs fail to 
proliferate and remain at the G0 phase of the cell cycle7,60.  
MSCs reduced DC secretion of pro-inflammatory cytokines such as IFN-γ, IL-12 and 
TNF-α70, inhibit the regulation of APC-related molecules such as HLA-DR, CD1a, CD14, 
CD40, CD80, CD83 and CD86 antigens on their surface during the maturation stage50 and 
increased IL-10 leading to the inhibition of DCs maturation and the capacity to activate 
alloreactive T cells resulting in a state of an immunologic tolerance51.  
Cell contact via surface ligands involving activation of the Notch signalling pathway51 
and soluble factors enhanced the efficiency of this supression59. IL-6, macrophage-CSF and 
PGE2 are described to be involved in MSCs-mediated immunosuppression of DC 
differentiation from monocytes73. 
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1.5. Mechanotransduction  
The extracellular environment is an essential mediator of cell survival providing 
both biochemical and mechanical stimuli that influence cell behavior76. The composition 
and mechanical properties of the extracellular matrix (ECM) are essential for cellular 
processes such as proliferation, differentiation and other cell fate decisions77,78. The 
microenvironment can influence cells by the presence of not only biochemical stimuli but 
also by mechanical and physical stimuli79,80. Cell adhesion, actin flow, retraction forces or 
gene expression are also cellular processes influenced by substrate rigidity79,81. 
Mechanotransduction is by definition the mechanism by which cells transform 
mechanical signals by mechanosensitive receptors or structures that sense and convert 
them into biochemical responses (Figure 1.3)82,83. This can occur as a result of changes in 
the cell cytoskeleton or through a series of biochemical signalling cascades78.  
Figure 1.3: Schematic showing mechanotransduction in a Cell-ECM unit. Biophysical signals in the stem cell 
niche include matrix rigidity and topography, flow shear stress, strain forces, tensile forces actin through the 
ECM, and other mechanical forces exerted by adjacent support cells. Stem cells sense these signals through 
mechanosensors such as ion channels, focal adhesions (FA), cell surface receptors, and actin cytoskeleton 
and cell-cell adhesions. (Adapted from Jaalouk et al., 2009)  
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Biophysical stimuli in the stem cells niche include matrix rigidity and topography, 
shear forces associated with fluid flow over the cell, tensile forces acting through the ECM, 
and contractile forces generated by motor protein and cytoskeleton complexes84. These 
biophysical stimuli can be sensed by stem cells through mechanosensors such as ion 
channels, cell surface receptors, focal adhesions (FA), actin cytoskeleton and cell-cell 
adhesions85. The variety of mechanosensors in stem cells suggests that they have a robust 
ability to interact with their mechanical environment. MSCs can sense the rigidity of the 
ECM through generating contractile forces through adhesion complexes that connect 
intracellular structures to ECM86.  
Engler et al., provide a new approach to direct stem cell fate, demonstrating that 
matrix elasticity is enough to direct commitment of adult stem cells toward different 
lineages78,80. In 2010, a study from Gilbert et al., showed that the regenerative capacity of 
stem cells in vivo can be strongly influenced by the mechanical properties of the substrate 
where cells were cultured in vitro87 . A recent study from Yang and colleagues, using MSCs 
cultured on hydrogels with distinct degrees of stiffness, demonstrated that stem cells have 
mechanical memory and that YAP/TAZ (transcription factor) behave as an intracellular 
mechasensor78, by exiting the nucleus when cells were kept on soft environments and 
entering the nucleus when on stiff environments.  
 
1.5.1. Mechanisms of Mechanotransduction  
A dynamic relationship exists which allows the ECM to induce signals from the 
extracellular environment inside the cell and, conversely, signalling from inside the cell that 
eventually resulting in remodelling of the ECM. This dynamics is largely mediated by 
integrin binding to ECM proteins78. Integrins are transmembrane proteins heterodimers 
composed of an α- and a β-chain, which mediate the adhesion of cells to a diversity of ECM 
proteins ligands, including fibronectin, collagen, laminin and vitronectin79. Cells sense 
extracellular stiffness using integrins to attach to the ECM and by generating traction forces 
via actomyosin contractility, hence sensing the corresponding reaction force generated by 
the environment. Currently it is known that the integrin receptor itself switches to a high-
affinity state in response to force88.  
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Mechanotransduction initiates at focal adhesions (FA), a dynamic structure that 
binds to the ECM, which is formed by coordinated recruitment of intracellular adaptor and 
catalytic proteins linked to ECM proteins through integrins (Figure 1.4 and figure 1.5)79,85.  
In response to a mechanical stimulus, many enzymes change their kinetics, like focal 
adhesion kinase (FAK), whose activity increases with mechanical stimuli79. This enzyme 
interacts with integrins and phosphorylates tyrosine residues of intracellular proteins, 
promoting their recruitment to FA. 
 
 
Figure 1.4: Focal Adhesion structure. Schematic representation of focal adhesion structure that is formed by 
integrin, talin, paxilin (Pax), vinculin (Vin), focal adhesion kinase (FAK), zynix and vasodilator-stimulated 
phosphoprotein (VASP) and the actin cytoskeleton (in purple) bond to the FA. These molecules provide a 
direct physical link to the actin cytoskeleton. Talin binds to the cytoplasmic domain of the β integrin subunit, 
thereby triggering the transition of the entire α integrin –β integrin dimer from an inactive to an active 
conformation that is capable of high affinity interactions with ECM ligands.  (Adapted from Sun et al., 2012) 
 
After FA formation initiates, cells exert force on the substrate through actomyosin 
contraction, which results in movement of actin fibers. Depending on the rigidity of the 
substrate, talin may become stretched or not. On a stiff substrate, actomyosin induces 
tension, talin becomes stretched – hence revealing further domains for the binding of 
adapter proteins - resulting in reinforcement of early FAs, though the recruitment of more 
vinculin and other FA adapter proteins79.  In case of a soft substrate, talin does not become  
stretched, since the extracellular matrix deforms in response to the force exerted by the 
cell79.  
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Figure 1.5: Schematic actin cytoskeleton – FA interaction. (Step 1) Generated forces by actin polymerization 
and myosin II-dependent contractility affect specific proteins mechanosensors in the actin-linking module 
(such as talin or vinculin), the receptor module (integrins) and co-receptors, the associated actin-polymerizing 
(zynx) and the signalling module (FAK and p130CAS). These interacting molecules form a mechanoresponsive 
network. (Step2) The effect on the actin cytoskeleton depends on the integrated response of the entire 
system to interactions with the matrix and to applied mechanical forces. (Step 3) Stimulation of signalling 
module leads to activation of guanine nucleotide-exchange factors and GTPase-activating proteins, which 
leads to activation of small G proteins (namely Rho and Rac). (Step 4) Rho affects actin polymerization and 
actomyosin contractility through cytoskeleton-regulating proteins, thereby (step 5) modulating the force 
generating machinery. (Adapted from Geiger et al., 2009)  
 
Once focal adhesion kinase (FAK) becomes activated as a result of integrin 
activation, it could lead to the activation of MAP kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K) signalling pathways, regulating diverse cellular processes, such as 
proliferation, migration and differentiation89. Beyond that, FAK can also activate the RhoA 
pathway, which is involved in actin cytoskeleton tension. When RhoA is activated, recruit 
myosin II to bind actin cytoskeleton, that will increase cytoskeleton tension leading to a 
reinforcement of FAs88. The activity of RhoA seems to be altered by stiffness, altering the 
degree of myosin activation and the cellular contractility84.  
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Figure 1.6: Proteins involved in integrin-mediated rigidity sensing. After the formation of the FA, RhoA is 
activated by FAK and recruits myosin to bind actin cytoskeleton, increasing the cytoskeleton tension and 
resulting in the focal adhesion reinforcement. (Adapted from McMurray et al., 2014) 
 
 In summary, the process of mechanotransduction is composed by several 
mechanism that permit cells to sense their physical environment and respond accordingly.  
1.5.2. ECM Stifness and Biomaterials 
Cells generally show better in vitro behaviour when cultured on materials with 
stiffness similar to that their microenvironment, so the rigidity preferences of cells 
generally reflect their native enviroments79. In the human body, the elastic modulus of 
adult mammalian tissues ranges several orders, from < 1 kilopaascal (kPa) - or 1 nN/µm2 - 
for brain to MPa (Megapascal) for bone (Figure 1.7)76,90. The stiffness of the 
microenvironment has an important consequence in cellular processes such as spreading, 
morphology and function81. Stem cells can sense and respond to alterations of the elastic 
modulus of the ECM by modulating their endogenous cytoskeleton contractility, balanced 
by resistant forces which are generated by the deformation of the ECM85. MSCs sense and 
respond to substrate rigidity by exerting traction forces upon the binding between integrins 
and integrin-specific ligands that are present on the substrate surface. The stiffness of 
biomaterials can be measured based on the force that is required to deform the matrix79. 
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Figure 1.7: Variations in tissue stiffness: tissues exhibit a range of stiffness, measured by the elastic 
(Young’s) modulus, E. (Adapted from Cox et al., 2011) 
 
In a biological context, elasticity or stiffness is often referred to as Young’s modulus 
(also known as Elastic modulus) E, that consists of the amount of force per unit area needed 
to deform the material by a given fractional amount without any permanent deformation, 
being a high elastic modulus corresponding to high stiffness and low deformability. To 
determine the elastic modulus, the force is applied perpendicular to the material’s surface, 
whereas for the shear modulus, (-G), the force is applied parallel to the surface (Figure 1.8).  
The Young’s modulus (E) can be calculated from the shear modulus,(both 
representing the amount of force per unit of area84) using the following equation : E= 2G(1+ 
v), where v is the Poisson ratio. 
In case of materials that do not change volume under stretch, like most rubber-like 
elastic materials, the Poisson ratio equals 0.5 and the elastic modulus will be three times 
its shear modulus, E=3G. The units for rigidity are force per area being the SI unit the 
Pascal79,84.  
 
 
 
 
 
 
 
 
 
C h a p t e r  1  -  I n t r o d u c t i o n  | 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Rigidity moduli. Stress is the amount of force that is applied per area (F/A) and the strain is the 
displacement in the direction of applied force relative to initial length (Δx/L or ΔL/L). Elastic and shear moduli 
are the ratio of stress over strain, the difference is in the direction of the applied force. (Adapted from Moore 
et al., 2010) 
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2. Aims  
 
The aim of this thesis is to understand if elements related to mechanotransduction 
influence immunomodulation induced by MSCs. Namely, we were interested to elucidate 
if MSCs derived from different substrates with distinct mechanical and biochemical 
properties possess different immunosuppressive capabilities and wether their action varies 
with the immune cell type.  
Any positive modulation of the immunomodulation capacity by MSCs from different 
substrates would represent an important contribution to the field.  
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3. Materials and Methods  
 
3.1. Isolation and culture of mesenchymal stem cells (MSCs) from human 
Wharton’s Jelly (WJ)  
 All the procedures concerning cell culture and manipulation of umbilical cord were 
performed under aseptic conditions using a class II vertical laminar airflow cabinet 
(HeraSafe HS-18, Heraeus).   
 Fresh human umbilical cord were obtained after birth, provided by Crioestaminal 
S.A and stored in a sterile 50mL conical tube (VWR International) for 12 to 48 hours before 
tissue processing (as described27. In detail, each umbilical cord was cut into sections about 
5cm long and then washed 2 or 3 times with sterile phosphate buffered saline (PBS, Life 
Technologies), to remove the blood. Subsequently, the vein and arteries were removed to 
avoid endothelial cell contamination and the Wharton’s jelly (WJ) was cut into fragments 
of 2-5mm with the help of a scalpel and forceps. Groups of 15 to 30 fragments were 
transferred to 21cm2 tissue culture plates (TCP, Corning-Costar) or to 21cm2 dishes with 
collagen-I (Merck) and Fibronectin (Merck) functionalized PDMS substrates and left to dry 
(30 minutes for TCP and 1 hour for the PDMS substrates) to promote the attachment of the 
fragments to the plastic or PDMS. Then, the MSC proliferation medium [Alpha-MEM (Life 
Technologies) supplemented with 10% volume/volume (v/v) MSC-qualified Fetal Bovine 
Serum (FBS, Hyclone), 10 U/ml Penicillin, 10µg/ml Streptomycin and 2,5 µg/mL 
Amphotericin B (all from Life Technologies)], pre-warmed in a 37°C water bath, was slowly 
added to the attached fragments until all the fragments were totally immersed. These 
fragments were maintained in culture for 15 to 20 days in an incubator at 37°C, in an aseptic 
environment with 5% CO2 and humidified atmosphere, until MSCs were migrating out of 
the hWJ fragments and forming well defined colonies, regularly adding the necessary 
volume medium (as needed) to keep them immersed. The cells that migrated out of hWJ 
were detached from the plastic and gel surface after removing the fragments and washing 
cells with PBS), using Trypsin (500µg/ml) – EDTA (200 µg/ml) solution (Life Technologies) 
during 5 minutes, at 37°C. The trypsin was inactivated with α-MEM with 10% (v/v) FBS (Life 
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Technologies) and then cells were re-suspended using a 5 ml serological pipette (Corning-
costar) for complete cell dissociation. Next, cells were centrifuged (290 x g 5 min), the pellet 
was re-suspended in MSC proliferation medium using a serological pipette in MSC 
proliferation medium, counted and plated in new TCP and PDMS dishes. For the passaging 
procedure cells were washed twice with PBS and then dissociated using Trypsin-EDTA 
solution (as described above) when reached around 70-80% of confluence. Cells were 
passaged until a maximum of passage 8 (P8). 
 MSC identify was confirmed by immunophenotype characterization and colony-
forming unit-fibroblast as described by Dominici et al.10.  
3.1.1. Cryopreservation of MSCs  
When cells reached around 80-90% of confluence were dissociated using Trypsin-
EDTA solution, then re-suspended with MSC proliferation medium and collected to a 
conical tube for centrifugation (290 x g, 5min). The supernatant was removed and the pellet 
was re-suspended in 1mL of freezing medium, constituted by FBS (Life Technologies) with 
10% (v/v) cell-culture tested DMSO (Sigma) and transferred into a cryopreservation vial 
(Nunc). The vial was frozen at -80°C overnight in an isopropanol-based cryo-cooler (VWR), 
to promote a gradual freezing (-1°C/min) and then transferred into a nitrogen cryotank, 
correctly identified with the cell type, passage number, corresponding thawing culture 
area, substrate type and freezing date.  
3.1.2. Proliferation kinetics of MSCs 
MSC isolated from WJ were continuously cultured from P2 to P8 and counted once 
they reached 70-80% confluence at each passage. The population doubling (PD) rate was 
determined ate each passage using the following equation91: 
 
𝑋 =
𝑙𝑜𝑔10 (𝑁𝐻)−𝑙𝑜𝑔10 (𝑁1)
𝑙𝑜𝑔10 (2)
          Equation 3.1 
 
NH represents the harvested cell number and N1 the plated cell number. The PD for 
each passage was calculated and added to the PD of the previous passage to generate data 
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for cumulative population doubling (CPD). The generation time (GT) (average time between 
two cells doublings) was also calculated, using the following equation91:  
 
𝑋 =  
𝑙𝑜𝑔10 (2) × ∆𝑡 
𝑙𝑜𝑔10 (𝑁𝐻)−𝑙𝑜𝑔10 (𝑁1)
      Equation 3.2  
 
The total number of cells (TNC) designates the theoretical number of cells that could 
be obtained if no cells were discarded between each passage. The TNC was determined at 
each passage by cumulative counting of the cells using the following formula: 
 
          𝑋 =  
𝑁𝐻 ×𝐵
𝑁1
                        Equation 3.3 
 
B represents the total number of cells of the previous passage. The TNC designates 
the theoretical number of cells that could be obtained if no cells were discarded between 
passages.  
3.1.3. Colony-forming unit-fibroblasts assay  
 The colony-forming unit-fibroblast (CFU-F) assay was determined at P2 and P8. Cells 
were seeded at 10 cells/cm2 on 55cm2 tissue culture plates in MSC proliferation medium 
and cultured for 15 days, one third of the medium was replaced twice a week. Then, cells 
were fixed with 4% PFA for 20 minutes at RT and stained with Giemsa solution (Sigma). 
Individual colonies were counted manually.   
3.1.4. Immunophenotypic study of hWJ-MSCs 
 The immunophenotypic characterization of MSCs was performed in collaboration 
with Centro Hospitalar da Universidade de Coimbra – Unidade de Gestão Operacional de 
Citometria and prior to co-cultures experiments. Cells were detached with Accutase® 
(LifeTechnologies), washed with PBS and the cell pellet was stained with monoclonal 
antibody (mAb) for surface protein antigens and, after an incubation period of 10 minutes 
in the dark at room temperature (RT), washed with PBS. Then, cells were ressuspended in 
250 µL of PBS and immediately acquired in a FACSCanto II (BD) flow cytometer. The mAb 
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used were conjugated with the following fluorochromes: fluorescein isothiocyanate (FITC), 
allophycocyanin (APC), phycoerythrin (PE), phycoerythrin-cyanine 7 (PECy7), krome orange 
(KO) and phycoerythrin-cyanine 5 (PerCPCy 5.5). The following monoclonal antibodies were 
used for the labelling: CD105 FITC (clone 2H6F11, Immunostep), CD90 APC (clone 5E10, BD 
Pharminogen), CD73 PE (clone AD2, BD Pharminogen), CD13 PECy7 (clone Immu103.44, 
Beckman Coulter), CD45 KO (clone J.33, Beckman Coulter) and CD34 PerCPCy 5.5 (clone 
581, BD Biosciences).  
3.2. Preparation and Functionalization of Polydimethylsiloxane (PDMS) for cell 
culture  
3.2.1. Preparation of PDMS  
 Polydimethylsiloxane (PDMS) is a biocompatible and nontoxic silicone elastomer. 
The elastic properties of this material can be easily tuned by changing the based/curing 
agent ratio to cover a wide range of physiologically-relevant elastic modulus for moduli for 
mechanobiological studies. 
PDMS monomer (Sylgard 184 Silicone Elastomer Kit, Dow Corning) was 
homogeneously mixed with its curing agent in the volume ratio of 10:1 and 40:1 (hereafter 
referred to as 1:10 and 1:40 PDMS substrates) followed by casting onto a polystyrene dish. 
This kit is a heat curable PDMS supplied as a two-part kit consisting of pre-polymer (base) 
and cross-linker (curing agent) components. The mixture was then degassed during 1 hour 
to remove all of the air bubbles and cured at 70°C for 4 hours in a heating incubator 
(Binder).  The substrate with 1:10 volume ratio has a stiffness around 1000 kPa and 1:40 
was a stiffness approximately around 80 kPa – the stiffness of TCP is around 1 gigapascal 
(GPa) 92 . 
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3.2.2. Treatment of Polydimethylsiloxane (PDMS) substrates for cell 
culture  
 PDMS is hydrophobic and provides extremely low adhesiveness to cells, making it 
necessary to chemically treat it in order to turn it more hydrophilic and to subsequently 
allow the covalent binding of ECM proteins (providing a stable bond between the substrate 
and the protein) providing an adequate environment for mammalian cell culture. 
For the hydrophilic treatment and functionalization the surface of PDMS substrates, 
the 1:10 substrates were detached from the casting dish and reversed in order to treat the 
smoother side (bottom part) of the substrate. The reason for this procedure was to avoid 
the roughness of the “upper side” of the substrate, which interfered with the cell culture, 
as also described in the literature93. In case of the 1:40 substrates, these were not detached 
and were treated in the casting dish, since the surface roughness of these PDMS substrates 
seemed to be lower and did not cause problems during MSC cell culture. The procedure for 
treatment of PDMS is summarized in Figure 3.193.  
 The hydrophilic treatment of PDMS was performed using a solution constituted by 
miliQ Water (H2O mQ)/ hydrochloric acid (HCl, Fluka)/hydrogen peroxide (H2O2, Sigma) in 
a volumetric proportion of (5:1:1) for the 1:40substrate and (3:1:1) for the 1:10 substrate. 
The solutions were prepared fresh and added to the PDMS surfaces, allowing the reaction 
to occur during 5minutes at RT, creating this way silanol groups on the PDMS surface.  
A silanol is a functional group in silicon chemistry with the connectivity Si–O–H. After this 
reaction, PDMS was washed three times with H2O mQ. In order to have a chemical 
functionalization of PDMS, a solution of 10% (v/v) 3-aminopropyltrimethoxisilane (APTMS) 
in 96% (v/v) ethanol (EtOH, Merck) was added to the substrates during 30 minutes at RT, 
followed by three abundant washes with H2O mQ 10 minutes each with agitation, in order 
to remove the excess of APTMS that otherwise would avoid the reaction between PDMS-
bond APTMS and glutaraldehyde (which was added on the following step).Then, a solution 
of 3% (v/v) glutaraldehyde in PBS 1x was added to the substrates and incubated for 20 
minutes at RT. After that, substrates were washed three times with abundant H2O mQ 5 
minutes each, with agitation. The chemical functionalization of PDMS with the crosslink of 
APTMS and glutaraldehyde leave one free aldehyde group that covalently binds to ECM 
protein, and leaving the PDMS substrate functionalized. The substrates 1:10 were cut and 
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placed in new-cell culture dishes. Afterwards, the substrate-containing dishes were 
exposed to ultraviolet (UV) light during 30 minutes in PBS and washed one time with PBS.  
Finally, a solution of 2920 µg/mL Collagen Type I (Merck) was added to 1:40 substrates and 
1000 µg/mL Fibronectin (Merck) plus 2920µg/mL Collagen Type I was added to 1:10 
substrates and then incubated for 2hours and 3 hours, respectively. The ECM protein 
composition described for each PDMS substrate was optimized for each condition.  
 
Figure 3. 1 Schematics of PDMS surface chemical modification. PDMS underwent a hydrophilic treatment 
using a H2O/HCl/H2O2 solution and then, the crosslink between APTMS and glutaraldehyde allows the 
covalent binding of ECM protein to the PDMS surface. (Adapted from Kuddannaya et al., 2013) 
 
 3.2.3. Cell Culture on TCP and PDMS substrates 
 After the isolation and expansion of MSCs on tissue culture plates (TCP), cells were 
split and re-plated on dthe distinct substrates (TCP, 1:10, 1:40 PDMS substrates) at 5x103 
cells/cm2 and maintained for 5 days in culture before being harvested for co-culture 
experiments with mononuclear cells (MNCs). Culture media were changed 24 hours before 
the co-culture experiments to serum-free α-MEM (supplemented with antibiotics), to 
obtain MSCs-conditioned media (CM). The distinct CM were then centrifuged (2900 x g, 5 
mint) and collected for multiplex cytokine analysis and for experiments using MNCs in 
presence of MSCs-conditioned media. 
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3.3. Multiplex Cytokine Analysis  
In order to analyse concentration of cytokines conditioned culture medium was 
collected from MSCs after24h with medium serum free and conditioned culture medium 
after 24h in direct contact with mononuclear cells, was also collected.  
The concentration of cytokines on conditioned cell culture medium were evaluated 
using a Bio-Plex Pro 8-Plex Panel Assay (Bio-Rad, Hercules), according to the manufacturer’s 
instructions and as detailed below, using a Bio-Plex 200 system (Bio-Rad). The 8-plex panel 
evaluated the presence of the following analytes: GM-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10 
and TNF-α. The procedure for multiplex cytokine analysis is summarized in Figure 3.293.  
Samples were, thawed on ice and homogenized using a microplate agitator (Asal 
715) and then processed as follows (according to the kit’s instructions). Samples were 
incubated at RT with agitation with the antibody-conjugated beads for 60 minutes and then 
washed three times using the kit wash buffer following vacuum aspiration. The incubation 
with detection antibodies was performed for 30 min (RT) with agitation, followed by three 
washed as before. Finally, the incubation with the antibody conjugate streptavidin-
phycoerythrin (SA-PE) was performed for 10 min (RT, with agitation), followed by three 
washes. The beads were re-suspended with assay buffer and data was acquired using a Bio-
Plex 200 system. Acquisition and analysis was performed using the software Bio-Plex 
Manager 5 (Bio-Rad). 
 
 
 
Figure 3. 2. Schematics summarizing the Bio-plex assays workflow. (Adapted from Biorad)  
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3.4. Immunophenotypic study of MSCs with Peripheral Blood Mononuclear 
Cells (MNCs) 
3.4.1. Collection and Isolation of Peripheral Blood Mononuclear Cells  
 Peripheral blood samples were obtained from a healthy donor (male, 38 years old), 
collected in heparin at the Instituto Português do Sangue e da Transplantação - Área de 
Transplantação (Portugal).  
Peripheral blood mononuclear cells (MNCs) were isolated by Histopaque (Sigma-
Aldrich) density gradient centrifugation (400 x g for 20 minutes) and then, washed in Hank’s 
Balanced Salt Solution (HBSS, Life Technologies). The MNCs pellet was re-suspended in 
RPMI 1640 with L-glutamine (Life Technologies) and antibiotic-antimycotic and then, 
counted in a hematology analyser (Coulter Ac-T diff2, Beckman Coulter) and subsequently 
plated 4x105 cells in 2 or 3 replicate wells per condition of 24 well tissue culture plates 
(Corning-costar). The cell culture and stimulation protocols are detailed below, in “Co-
culture of MSC and peripheral blood (MNC) and in vitro stimulation” section.  
3.4.2. Co-culture of MSCs and peripheral blood (MNCs) and In vitro 
stimulation  
 The co-culture of MSCs and peripheral blood (MNC) and in vitro stimulation was 
made in collaboration with Instituto Português do Sangue e da Transplantação - Área de 
Transplantação (Portugal).  
All the procedures concerning cell culture and manipulation were performed under 
sterile conditions using a class-II vertical air-flow cabinet. 
In 3 wells of 24 well tissue culture plates (Corning-costar) 4x105 MNCs were plated 
in 500 µL of RPMI 1640 (Invitrogen, Life Technologies) and 500µL of α-MEM with antibiotic-
antimycotic (Life Technologies), and in 6 others wells of tissue culture plates (Corning-
Costar) 2x105 MSCs + 4x105 MNCs (each well) were plated in a final volume of 1 mL (1:1 – 
RPMI:α-MEM) , establishing a ratio of 1:2 (MSCs:MNCs). Additionally, a parallel assay using 
MSCs-conditioned medium (CM obtained from MSCs during 24h, as detailed above) was 
also performed, adding 500 µL of CM and to the MNC cells. Cells were cultured for 20-24 
hours at 37°C, in an aseptic environment with 5% CO2 and humidified atmosphere. All 
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assays were performed using MSCs between passage P3 and P5. Control cultures consisted 
of MNCs in the absence of MSCs with or without stimulation.  
3.4.2.1. In vitro stimulation with Phorbol myristate acetate (PMA) 
plus ionomycin  
Phorbol myristate acetate (PMA) is a small organic compound that diffuses through 
the cell membrane into the cytoplasma, where it directly activates protein kinase C (PKC) 
omitting the “need” of surface receptor stimulation. Ionomycin, calcium ionophor, is used 
in addition to trigger calcium release which is needed for NFAT signalling.  
After the incubation period (detailed in material an methods section above), 50 
ng/mL PMA plus 1 µg/ml ionomycin (Sigma-Aldrich and Boehringer, respectively) were 
added to the wells with MNCs and MNCs+MSCs. Brefeldin A (10 µg/mL) from Penicillium 
brefeldiamun (Sigma-Aldrich), is a protein transport inhibitor, was added to the wells to 
prevent the secretion of de novo produced cytokines outside the cells by MNCs, blocking 
the transport processes during cell activation leading to accumulation of most cytokines at 
the Golgi complex/Endoplasmatic reticulum. Then, proceeded to an incubation at 37°C, in 
an aseptic environment with 5% CO2 and humidified atmosphere, for 4 hours. These 
samples were used to study cytokine expression on T cells compartments (naïve, central 
memory, effector memory and effector cells) by flow cytometry.  
3.4.2.2. In vitro stimulation with Lipopolysaccharide (LPS) plus 
interferon- gamma (IFN-γ) 
 Lipopolysaccharide (LPS) is the major component of the outer membrane of Gram-
negative bacteria and is one of the most potent stimuli for monocytes.  
After the incubation period, 100 ng/ml lipopolysaccharide (LPS) plus 100 U/mL IFN-
γ were added to the wells with MNCs and MNCs+MSCs. Brefeldin A (10 µg/mL) from 
Penicillium brefeldiamun (Sigma-Aldrich) was added to the wells to prevent the secretion 
of de novo produced cytokines outside the cells. Then, the samples were incubated at 37°C, 
in an aseptic environment with 5% CO2 and humidified atmosphere, for 6 hours. These 
samples were used to study cytokine expression on monocytes by flow cytometry. 
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3.4.3. Immunophenotypic analysis of MNCs 
 After the incubation period for in vitro stimulation, the content of each well under 
different experimental condition was transferred to a 12x75mm polysterene cytometer 
tube, centrifuged (540 x g for 5 minutes). Immunophenotypic study of peripheral blood T 
cells and monocytes was perfomed using 8-color mAb combinations, as detailed in Table 
3.1. Cell pellet were stained with mAB for surface proteins antigens. For intracellular 
staining, Intraprep Permeabilization Reagent (Beckamn Coulter) was used, according to the 
manufacter’s instructions and in parallel with the mAb, for T cells IL-2 and TNF-α (tube 1), 
and for monocytes TNF-α (tube 2). After washing twice with PBS, the cell pellet was 
resuspended in 250µL of PBS and immediately acquired.  
Table 3. 1. Panel of mAb reagents (with clones and commercial sources) used for the immunophenotypic 
characterization  
T
u
b
e 
Fluorochromes 
PacB KO FITC PE PerCPCy 
5.5 or 
PECy5 
PECy7 APC APCH7 V500 
1 CD3 
UCHT1 
BD Pharmingen 
- IL-2 
MQ1-17H12 
BD 
Pharmingen 
TNF-α 
Mab11 
BD 
Pharmingen 
 
CD27 
1A4CD27 
Beckman 
Coulter 
CD56 
N901 
Beckman 
Coulter 
CD45RA 
HI100 
BD Pharmingen 
CD4 
SK3 
BD 
Bioscience
s 
CD8 
RPA-T8 
BD 
Horizon 
2 HLA-DR 
L243 
BD Pharmingen 
CD45 
J.33 
Beckman 
Coulter 
CD35 
E11 
BD 
Parmingen 
TNF- α 
Mab11 
BD 
Pharmingen 
CD11C 
B-ly6 
BD Biosciences 
CD33 
D3HL60.25
1 
Beckman 
Coulter 
IREM-2 
UP-H2 
Immunostep 
CD14 
MφP9 
BD 
Bioscience
s 
 
-  
 
Abbreviations:  mAb, monoclonal antibody; PacB, pacific blue; KO, krome orange; FITC, fluorescein 
isothiocyanate; PE, phycoerythrin, PerCPCy 5.5, peridin chrophyll protein cyanine 5.5; PECy5, 
phycoerythrin-cyanine 5 ; PECy7, phycoerythrin-cyanine 7; APC, allophycocyanin; APCH7, 
allophycocyanin-hilite 7. Comercial sources: BD Pharmingen (San Diego,CA,USA); BD Bioscience 
(Becton Dickinson Biosciences, San Jose, CA,USA); Beckman Coulter (Miami, FL, USA). 
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3.5. Data Acquisition and analysis  
Data acquisition were perfomed in a FACsCAnto™II (BD) flow cytometer equipped 
with the FACSDiva software (v6.1.2; BD) at Centro Hospital da Universidade de Coimbra – 
Unidade de Gestão Operacional de Citometria. For the immunophenotypic studies, the 
whole sample from each tube was acquired and stored. For data analysis, the Infinicyt 
(version 1.7) software (Cytognos SL, Salamanca, Spain) was used.  
3.6. Statistical analysis  
Statistical analysis was performed using the Graph Pad Prism 6 software.  Kruskal-
Wallis test followed by Dunn’s multiple comparison test was performed when data was not 
normal (non-parametric analysis). When appropriate t-test was used, to assess the 
normality of the data, Shapiro-Wilk’s test was performed. Values represent mean ± SEM 
and statistically significant differences were considered when p value was lower than 0.05. 
  
 
  
 
 
 
 
 
 
 
 
Chapter 4 - Results  
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4. Results  
4.1. Isolation and of mesenchymal stem cells (MSCs) from the Wharton’s jelly 
(WJ) 
 In the first part of this work, the objective was to isolate mesenchymal stem cells 
(MSCs) from the WJ in polydimethylsiloxane (PDMS) substrates polymerized on cell culture 
dishes with different formulations and in tissue culture plates made of polystyrene (TCP). 
Human MSCs were isolated from, as described in the Materials and methods section 3.1. 
At the end of 10-15 days in culture, several WJ fragments were still attached to the culture 
dishes and showed cells migrating from the tissue. After cells migration from the tissue, 
formed colonies of cells displaying an MSC-like phenotype, with spindle-shaped 
morphology and could be identify by phase-contrast microscopy (Fig.4.1).  
 
 
Figure 4. 1. MSCs like cells migrating from Wharton’s jelly fragments in proliferation medium, passage 
0. A) Isolation in tissue culture plates (TCPs); B) Isolation in 1:10 PDMS platform; C) Isolation in 1:40 PDMS 
platform  
A B 
C 
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Despite the fact that isolation in PDMS was successful, there were some difficulties 
to proliferate the cells in the different substrates, further optimization is needed. Put that, 
for the aim of this project, WJ-MSCs were isolated in TCP, proliferate and then, plated at 
the different substrates 5 days, as described in materials and methods section 3.2.4.  
4.2. Proliferation kinetics  
 A proliferation kinetics study was made with the purpose of characterizing the 
proliferation and evaluate the expansion capacity of isolated MSCs, since MSCs are cells 
with a higher proliferative capacity9. Cells were isolated from 4 distinct human Wharton’s 
jelly samples (UC#819, UC#841, UC#874 and UC#875). The population doubling (PD) and 
cumulative population doubling (CPD), generation time (GT) and total number of cells (TNC) 
of 4 independent samples were calculated from passages 2 to 8, as described in materials 
and methods section 3.1.3. 
As shown in figure 4.2, after 8 passages, the MSCs analysed had doubled their 
population by 18.77 ± 1.77 times (Fig.4.2-B), during which the observed mean generation 
time (GT) was between 1.02 ± 1.46 and 1.66 ± 0.48 days and no statistically significant 
differences were found in GT from passages 2 to 8 (Figure 4.2-C), as previously seen27. The 
total number of cells obtained (if no cells had been discarded until that point) during these 
passages was 2.17 x 1012 ± 1.25 x1012 cells (Fig.3.2- D).  Hence, the MSCs isolated show high 
proliferative capacity, maintaining a short generation time from passages 2 to 8. 
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Figure 4. 2. Proliferation kinetics study of Wharton’s Jelly-mesenchymal stem cells (WJ-MSCs) in vitro. From 
passage 2 (P2) onwards (inclusively), cells were plated at a fixed density of 4000 cells/cm2, allowed to 
proliferate until 70-80% confluence and re-plated the same way. (A) The population doubling (PD) was 
determined using the formula X= [log10 (NH)-log10 (N1)/log10 (2). (B) Cumulative population doubling (CPD) 
was determined by adding the calculated PD to the PD levels of the previous passage. (C) The generation of 
time (GT) was calculated at passages 2 to 8, using the formula X= (log2 x Δt/ log10 (NH)-logq10 (N1). (D) The 
total number of cells (TNC) was determined at each passage (P1-P8) by cumulative counting the cells once 
they reached confluence of 70-80%. For each assay, 4 independent samples were used. Bars represent mean 
± SEM.  
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4.3. Colony forming unit-fibroblasts (CFU-F) capacity  
 One of these cells’ characteristics have is the ability to form colonies, when seeded 
at low density to eliminate cell-cell interactions. In order to assess this ability, cells were 
seeded at a very low density, 10 cell/cm2, at passages 2 and 8 and cultured for 15 days, as 
described in the materials and methods section 3.1.4. 
 
Figure 4. 3. CFU-F capacity of WJ-MSCs. The CFU-F capacity was determined by counting manually the 
number of colonies formed after 15 days in culture at low density of cells (10 cells/cm2) obtained at passages 
2 and 8. Results are representative of 4 independent samples. No significant differences were found 
performing two-tailed Mann-Whitney test. Bars represent mean ± SEM. 
 
As shown in figure 4.3, the four samples have great ability of forming colonies at 
passages 2 and 8 (45 ± 6.96 and 28 ± 3.43). In all samples the CFU-F capacity decreases at 
passage 8, although no statistically significant differences were found. 
4.4. Immunophenotypic characterization of WJ-MSCs  
 In order to determine if the cells isolated from Wharton’s jelly were bona fide MSCs, 
the expression of cell surface antigen was evaluated on 4 independent samples before the 
co-culture assay. The cells were cultured until subconfluency, dissociated using accutase 
and labelled with antibodies against cell surface markers typically used for the 
characterization of MSCs and analysed by flow cytometry (Table 4.1).  
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Table 4. 1. Summary of the flow cytometry analysis of WJ-MSCs 
Positive markers Negative markers 
CD13 CD34 
CD73 CD45 
CD90 
CD105 
 
Flow cytometry analysis showed that the cells isolated from WJ were positive for 
CD13, CD73, CD90 and CD105 (Fig 4.4). In contrast, the cells did not expressed CD34 
(hematopoietic lineage marker) and CD45 (leukocyte marker) (Fig.4.4). This analysis (Table 
4.1 and Fig.4.4) show that this phenotypic profile was consistent with the MSC phenotype 
previously described10,27. CD105 marker it’s not strongly positive due to the chosen 
fluorochrome, a different one should have been used, for example CD105 PE.  
 
Figure 4. 4. Illustrative immunophenotypic characterization of hWJ-MSCs. Cells were dissociated using 
accutase, labelled with antibodies against the indicated antigens and analysed by flow cytometry. Cells were 
positive for CD13 (A), CD73 (B), CD90 (C) and CD105 (D) and negative for CD34 (E) and CD45 (F) (blue lines) 
when compared with unlabelled MSCs (green lines), as depicted in the histograms. Histograms were obtained 
from one sample at passage 3 and are representative of 4 independent samples at P3. 
 
The cells obtained from the hWJ behave as MSCs, in other words, they are adherent 
to plastic, have high proliferative potential and CFU-F capacity, and typical 
immunophenotype signature of MSCs.    
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4.5. Multiplex cytokine analysis  
 MSCs produce a myriad of cytokines and in order to assess the impact of substrate 
stiffness on the secretory prolife of MSCs, conditioned culture medium was collected and 
assayed for a 8-plex panel evaluating the presence of the following analytes: GM-CSF, IFN-
γ, IL-2, IL-4, IL-6, IL-8, IL-10 and TNF-α.  The conditioned culture medium from co-culture of 
MSCs with MNCs after 24h in direct contact was also assayed for this same 8-plex panel.  
 As shown in figure 4.5 and 4.6, WJ-MSCs differentially secrete soluble factors in 
response to matrix compliance. It notable that MSCs isolated from hWJ secrete in high 
concentration IL-6 and IL-8 (as described in the literature94,95) and at a very low 
concentration IL-10 (which is also described in the literature that it is secreted by MSCs)53,64. 
MSCs showed a tendency to secret higher concentrations of IL-2, IL-4, IL-6 and IL-8 when 
cultured on 1:40 PDMS and 1:10 PDMS substrate than when maintained on standard tissue 
culture plate (TCP). Statistically significance differences were found for IL-2, IL-4 and IL-6 in 
cells cultured on 1:40 PDMS substrates when compared with TCP (but not between 1.10 
PDMS and TCP conditions) – Figure 4.5. Despite the fact that it is described that MSCs do 
not secrete IL-2 or IL-4, they could be detected at a very low concentration using a BioPlex 
assay, which is particularly sensitive (pg/ml range). 
 To rule out any putative effect caused by a possibly distinct number of cells that 
could be contributing to the overall cytokine secretion due to eventually distinct 
proliferation rates on the distinct substrates, cytokine concentration was normalized to the 
final number of cells present in each condition, and the results obtained (Figure 4.6) were 
similar to the raw data, except that for IL-6 the p value when comparing 1.40 PDMS with 
TCP was equal to 0.05 and not lower (as for the raw values – Figure 4.5) 
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Figure 4. 5.  Cytokines produced by Mesenchymal stem cells (MSCs) cultured on different substrates. Cells 
were plated (5 x 104 cells/cm2) on respective substrates and medium was conditioned for 24h, and then 
collected and analyzed. (A) Concentration of cytokines secreted by MSC. (B) Fold change of concentration 
compared to concentration of TCP. Bars represent mean ± SEM. Results are representative of 4 independent 
samples for TCP and 1:40 PDMS and 3 independent samples for 1:10 PDMS. Statistically analysis was 
performed by Kruskal-Wallis one way ANOVA followed by Dunn’s Multiple Comparison test (*< P 0.05). MSC, 
mesenchymal stem cells; IL, interleukin; TNF-α, tumor necrosis factor-α; IFN-γ, interferon γ; TCP, tissue 
culture plate.  
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Figure 4. 6. Cytokines produced by Mesenchymal stem cells (MSCs) cultured on different substrates. Cells 
were plated (5 x 104 cells/cm2) on respective substrates and medium was conditioned for 24h, and then 
collected and analysed. The amount of culture medium assayed was normalized to final cell number. (A) 
Concentration of cytokines secreted by MSC. (B) Fold change of concentration per million of cells compared 
to concentration per million of cells from TCP. Bars represent mean ± SEM. Results are representative of 4 
independent experiments for TCP and 1:40 PDMS and 3 independent experiments for 1:10 PDMS. Statistically 
analysis was performed by Kruskal-Wallis one way ANOVA followed by Dunn’s Multiple Comparison test (* P 
<0.05). MSC, mesenchymal stem cells; IL, interleukin; TNF-α, tumor necrosis factor-α; IFN-γ, interferon γ; TCP, 
tissue culture plates.  
 
 
Since 1:40 PDMS substrate revealed more differences in the cytokines secreted than 
1:10 PDMS substrate, only 1:40 PDMS was analysed in co-cultured with MNCs during 24h 
without any in vitro stimulation, as described above in materials and methods section 3.3. 
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Figure 4. 7. Cytokines produced in co-cultured of mesenchymal stem cells (MSCs) with peripheral blood 
(MNCs). MSC previously cultured on different substrates (TCP or 1:40 PDMS, as indicated) were co-cultured 
with MNCs during 24h in direct contact without any stimulation in vitro. After 24h in co-cultured, conditioned 
culture medium was collected and analysed. (A) Cytokines produced after 24h in direct contact. (B) Fold 
change of cytokine concentration compared to concentration of control (TCP). Results are representative of 
3 independent experiments. Statistically analysis was performed by t-test (* P < 0.05). MSC, mesenchymal 
stem cells; IL, interleukin; GM-CSF. Granulocyte macrophage- colony stimulator factor; TNF-α, tumour 
necrosis factor-α; IFN-γ, interferon γ; TCP, tissue culture plate standard. 
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 MNCs were co-cultured with MSCs in the absence of activating stimuli. It could be 
observed that when MSCs had been previously maintained on 1:40 PDMS substrates, there 
was a significant increase of IL-4 and IL-8 secretion when compared to the condition in 
which MSCs had been cultured on TCP (both in case of raw data – Figure 4.7-A – or fold 
change relative to control – Figure 4.7-B). A similar tendency was observed for GM-CSF and 
IL-10 secretion, although in this case no statistically differences were found (Figure 4.7). 
When data was normalized to the number of cells, the same was observed (Figure 4.8). This 
normalization according to total cell number allowed comparing the secretory profile of 
MNCs alone with ttat of MNCs in co-culture with MSCs obtained from TCP or 1:40 PDMS 
substrates, as represented in Figure 4.9.  
 As shown in figure 4.9, comparing with MNCs alone when MNCs were co-cultured 
with WJ-MSCs a notable increased in all cytokine under analysis (except for TNF-α), 
Statistically significant differences were observed for the concentration of IL-2, IL-4, IL-10 
and IFN-γ present in the conditioned medium when WJ-MSCs were previously cultured on 
1:40 PDMS (but not TCP) and then co-cultured with MNCs, when compared with MNCs 
alone. These results suggest that the cytokine context of MNCs alone or in co-culture with 
MSCs, especially with MSCs previously cultured on 1:40 PDMS substrates is significantly 
different.  
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Figure 4. 8. Cytokines produced in co-culture of mesenchymal stem cells (MSCs) with peripheral blood 
(MNCs). MSC previously cultured on different substrates (TCP or 1:40 PDMS, as indicated) were co-cultured 
with MNCs during 24h in direct contact (without any stimulation in vitro). After 24h in co-cultured, 
conditioned culture medium was collected and analysed. The amount of culture medium assayed was 
normalized to the sum of cell number of MNCs and MSCs plated. (A) Cytokines produced after 24h in direct 
contact. (B) Fold change of cytokine concentration per million of cells compared to concentration from TCP. 
Results are representative of 3 independent experiments. Statistically analysis was performed by t-test (* P< 
0.05).MSC, mesenchymal stem cells; MNCs, Mononuclear cells; IL, interleukin; GM-CSF. Granulocyte 
macrophage- colony stimulator factor; TNF-α, tumour necrosis factor-α; IFN-γ, interferon γ; TCP, tissue 
culture plate. 
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Figure 4. 9. Cytokines expressed in peripheral blood (MNCs) and in co-culture of mesenchymal stem cells 
(MSCs) with MNCs. MNCs were culture 24h alone without any stimulation in vitro and MSC previously 
cultured from different substrates (TCP or 1:40 PDMS , as previously indicated) were co-cultured with MNCs 
during 24h in direct contact without any stimulation in vitro. After 24h, both conditioned culture medium was 
collected and analysed. The amount of culture medium assayed was normalized to the sum of cell number of 
MNCs and MSCs plated. Results are representative of 4 independent experiments to MNCs and 3 
independent experiments to MSC in co-cultured with MNCs. Statistically analysis was performed by Kruskal-
Wallis one way ANOVA followed by Dunn’s Multiple Comparison test (* P <0,05; ** P < 0,001). MSC, 
mesenchymal stem cells; MNCs, Mononuclear cells; IL, interleukin; GM-CSF. Granulocyte macrophage- colony 
stimulator factor; TNF-α, tumor necrosis factor-α; IFN-γ, interferon γ; TCP, tissue culture plate. 
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4.6. Co-culture of peripheral blood MNCsand MSCs and in vitro with Phorbol 
myristate acetate (PMA) plus ionomycin 
 To the best of our knowledge, no study to date investigated and compared the 
influence of MSC cultured on different substrates over the peripheral blood T cells 
subpopulations. Several studies have demonstrated that MSCs have immunoregulatory 
effects on T cells (although few studies have studied the different T cell compartment) and 
in order to better understand how MSC cultured on different substrates regulate the 
immune function of the different T cell compartments [naïve, central memory (CM), 
effector memory (EM) and effector cells]. To investigate that, PMA+ ionomycin-stimulated 
MNCs were cultured in absence or presence of MSCs previously cultured on the different 
substrates (TCP, 1:10 PDMS or 1:40 PDMS). The control consisted on stimulated MNCs 
alone and stimulated MNCs + MSCs cultured on tissue culture plates (TCP). In order to 
identify the four abovementioned compartments among CD4+ and CD8+ T cells, 8-color 
mAb combinations was used (described in materials and methods 3.3.3 section) to 
analysed the protein expression of IL-2 and TNF-α within each cell compartment. The 
results obtained are preliminary, consisting of a limited number of independent 
experiments and for that reason, the interpretation of the results will also be based on the 
tendencies observed so far, with no possible statistical analysis.  
 The functional compartments of CD4+ and CD8+ T cells (imunophenotypically 
characterized as CD3+CD4+CD8- and CD3+CD4-CD8+, respectively) were identified according 
to their differential expression of CD45RA and CD27, as follows: naïve T cells were 
characterized by CD45RA+ CD27+ expression, CM T cells by CD45RA- CD27+, EM and effector 
T cells by CD45RA- CD27- and CD45RA+ CD27-, respectively.  
 As shown in figure 4.10 and 4.11, the presence of WJ-MSCs decrease the 
percentage of both CD4+ and CD8+ T cells expressing IL-2 or TNF-α (after stimulation of the 
MNCs with PMA + ionomycin) in the distinct compartments analysed.  The co-cultures of 
MNCs with WJ-MSCs derived from distinct substrates led to different levels of decreased 
percentage of both CD4+ and CD8+ T cells expressing IL-2 (Figure 4.10), but not in case of 
TNF-α (Figure 4.11), in which the MSCs obtained from distinct substrate appear to produce 
the same inhibitory effect. In detail, MSCs previously cultured on 1:10 or 1:40 PDMS 
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substrates seems to have a higher inhibitory effect over the percentage of IL-2 expressing 
CD4+ or CD8+ cells than MSCs cultured on TCPs (Figure 4.10). As shown in figure 4.10, WJ-
MSCs derived from both PDMS substrate (1:10 or 1:40) seem to decrease more the 
percentage of CD4+ T cells expressing IL-2 in all compartments – showing a higher tendency 
for immunosuppression, namely in case 1:40 PDMS - except for the naïve functional 
compartment, where the results are comparable with WJ-MSCs derived from TCP. 
Regarding CD8+ T cells, WJ-MSCs derived from the PDMS substrates decreased the 
percentage of cells expressing IL-2 in the naïve, central memory, effector memory and 
effector functional to a greater extent than MSCs cultured from TCP (Figure 4.11). In the 
effector functional compartment CD4+ T cells there was no detection of IL-2 or TNF-α 
positive cells, and for that reason, that functional compartment is not represented (Figure 
4.10).  
Concerning TNF-α, figure 4. 11 showed that the presence of WJ-MSCS decreased 
the percentage of cells expressing this cytokines in all functional compartments in both 
CD4+ and CD8+ T cells.Comparing the effect of MSCs obtained from the distinct susbtrates, 
all seem to present similar immunosuppression in all compartments and in  CD4+ and CD8+. 
In order to evaluate the soluble factors (alone) secreted by WJ-MSCs influence 
MNCs, the latter were culture and then stimulated in the presence of MSC-conditioned 
medium (as described in materials and methods section 3.4.2). As shown in figure 4.12 no 
effect seems to have to occured in the percentage of IL-2 producing in CD4+, although a 
slight decrease was observed in the amount of protein per cell (measured by mean 
fluorescence of intensity - MFI) except for the naïve functional compartment.  Concerning 
the percentage of IL-2 producing in CD8+ T cells there is no decrease observed in any 
functional compartment. Only in the amount of protein produced per cells (refelected by 
IL-2 MFI) a decrease was observed in all compartments except for effector CD8+ T cells.  
Concerning the percentage of TNF-α, producing cells, a slight decreasedwas observed in all 
the functional compartment, except for naïve compartment of both CD4+ and CD8+ T cells, 
with the same trend in terms of amount protein per cells (MFI-) – Figure 4.13.  
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 Figure 4. 10. Percentage of CD4+ and CD8+ T cells expressing Interleukin-2 (IL-2) determined by flow 
cytometry. MNCs were stimulated with PMA and ionomycin (MNCs + PMA + ionomycin) in the absence or 
presence of WJ-MSCs derived from different substrates, as indicated. The upper panels show the percentage 
of CD4+ and CD8+ T cells, producing IL-2, distributed among their functional compartments. The middle panels 
depicts the mean fluorescence intensity (MFI) of the signal, correlating with the amount of IL-2 expressed per 
cell. The lower panel represents the percentage of inhibition induced by WJ-MSCs on the distinct functional 
compartment of CD4+ and CD8+ T cell expressing IL-2. Results are representative of 2 independent 
experiments for TCP and 1:40 PDMS and 1 independent experiment for 1:10 PDMS. Bars represent mean ± 
SEM. CM, central memory; EM, effector memory; N.D., not determined) 
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Figure 4. 11. Percentage of CD4+ and CD8+ T cells expressing Tumour necrosis factor- alpha (TNF-α) 
determined by flow cytometry. MNCs were stimulated with PMA and ionomycin (MNCs + PMA + ionomycin) 
in the absence or presence of WJ-MSCs derived from different substrates, as indicated. The upper panels 
show the percentage of CD4+ and CD8+ T cells, producing TNF-α, distributed among their functional 
compartments. The middle panels depicts the mean fluorescence intensity (MFI) of the signal, correlating 
with the amount of TNF-α expressed per cell. The lower panel represents the percentage of inhibition induced 
by WJ-MSCs on the distinct functional compartment of CD4+ and CD8+ T cell expressing TNF-α. Results are 
representative of 2 independent experiment for TCP and 1:40 PDMS and 1 independent experiment for 1:10 
PDMS. Bars represent mean ± SEM. CM, central memory; EM, effector memory; N.D., not determined  
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Figure 4. 12. Percentage of CD4+ and CD8+ T cells expressing Interleukin-2 (IL-2) determined by flow 
cytometry. MNCs were stimulated with PMA and ionomycin (MNCs + PMA + ionomycin) in the absence or 
presence of MSC-conditioned medium derived from different substrates, as indicated. The upper panels show 
the percentage of CD4+ and CD8+ T cells, producing IL-2, distributed among their functional compartments. 
The middle panels depicts the mean fluorescence intensity (MFI) of the signal, correlating with the amount 
of IL-2 expressed per cell. The lower panel represents the percentage of inhibition induced by MSC-
conditioned medium on the distinct functional compartment of CD4+ and CD8+ T cell expressing IL-2. Results 
are representative of 2 independent experiments. Bars represent mean ± SEM. CM, central memory; EM, 
effector memory;  
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Figure 4. 13. Percentage of CD4+ and CD8+ T cells expressing Tumor necrosis factor-alpha (TNF-α) 
determined by flow cytometry. MNCs were stimulated with PMA and ionomycin (MNCs + PMA + ionomycin) 
in the absence or presence of MSC-conditioned medium derived from different substrates, as indicated. The 
upper panels show the percentage of CD4+ and CD8+ T cells, producing TNF-α, distributed among their 
functional compartments. The middle panels depicts the mean fluorescence intensity (MFI) of the signal, 
correlating with the amount of TNF-α expressed per cell. The lower panel represents the percentage of 
inhibition induced by MSC-conditioned medium on the distinct functional compartment of CD4+ and CD8+ T 
cell expressing TNF-α. Results are representative of 2 independent experiments. Bars represent mean ± SEM. 
CM, central memory; EM, effector memory;  
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4.7. Co-culture of peripheral blood MNCs and MSC in vitro with LPS plus IFN-γ 
To the best of our knowledge, no study to date investigated and compared the 
influence of MSC cultured on different substrates over the peripheral blood monocytes 
population.  In order to better understand if MSC cultured on distinct substrates regulated 
the immune function of monocytes, LPS+IFN-γ-stimulated MNCs were cultured in absence 
or presence of WJ-MSCs cultured on the distinct substrates (TCP, 1:10 and 1:40 PDMS). The 
control consisted of stimulated MNCs alone and stimulated MNCs + MSCs previously 
cultured on tissue culture plated (TCP). An 8-color mAb combinations was used (described 
in materials and methods 3.3.3 section) to analyse the percentage of TNF-α cells. The 
results obtained are preliminary, consisting of a limited number of independent 
experiments and for that reason, the interpretation of the results will also be based on the 
tendencies observed so far, with no possible statistical analysis. 
Figure 4. 14. Production of TNF-α by stimulated monocytes with LPS plus IFN-γ, under the following 
conditions: MSCs derived from different substrates co-cultured with MNCs and in vitro stimulation (A) 
Percentage of cells producing TNF-α for activated monocyte with LPS plus IFN-γ. (B) Amount of protein 
expressed per cell, measured as mean fluorescence intensity (MFI) for activated monocyte with LPS plus IFN-
γ. Results are representative of 3 independent experiments for TCP and 1:40 PDMS substrates and two 
independent experiments for 1:10 PDMS substrates. No significant differences were found performing 
Kruskal-Wallis one way ANOVA followed by Dunn’s Multiple Comparison test (compared with TCP). Bars 
represent mean ± SEM. 
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As shown in figure 4.14, the WJ-MSCs derived from TCP co-cultured with MNCs with 
in vitro stimulation with LPS + IFN-γ showed a very slight decrease in percentage of cells 
producing TNF-α (74.4 ± 10.2) comparing with the PDMS substrates - 1:10 PDMS (59.4 ± 
39.4) and 1:40 PDMS (58.1 ± 17.5).  
 Observing the figure 4.15 that corresponds to monocytes cultured and 
stimulated in presence of MSCs-conditioned medium, the CM obtained from TCP –derived 
MSCs showed less percentage of cells producing TNF-α (50.2 ± 47.1) compared with the 
1:10 PDMS and 1:40 PDMS, (77.7 ± 11.7) and (59.5 ± 25.7), respectively. Observing figure 
4.16, monocytes cultured and stimulated in presence of MSCs-conditioned medium appear 
to not have any differences in the producing of TNF-α. 
 
Figure 4. 15. Production of TNF-α by monocytes stimulated with LPS plus IFN-γ, under the following 
conditions: MSC-conditioned medium derived from different substrates co-cultured with MNCs and in vitro 
stimulation (A) Percentage of cells producing TNF-α for activated monocyte with LPS plus IFN-γ. (B) Amount 
of protein expressed per cell, measured as mean fluorescence intensity (MFI) for activated monocyte with 
LPS plus IFN-γ. Results are representative of 3 independent experiments for 1:40 PDMS MSC-conditioned 
medium and 2 independent experiments for TCP MSC-conditioned medium and 1:10 PDMS MSC-conditioned 
medium. Bars represent mean ± SEM. 
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Figure 4. 16. Production of TNF-α by monocytes stimulated with LPS plus IFN-γ co-culture with MSCs 
derived from different substrates and the respective MSCs-conditioned medium. Percentage of cells 
producing TNF-α. Results are representative of 3 independent experiments for TCP and 1:40 PDMS substrates 
and 2 independent experiments for 1:10 PDMS substrates and 3 independent experiments for 1:40 PDMS 
MSC-conditioned medium substrates and 2 independent experiments for TCP MSC-conditioned medium and 
1:10 PDMS MSC-conditioned medium. Bars represent mean ± SEM. CM, Conditioned medium.  
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5. Discussion    
 
Human Wharton’s Jelly  mesenchymal stem cells (hWJs-MSCs)  were isolated with 
100% efficiency and  the cells exhibited low generation time and proliferated readily up to 
at least 8 passages – P8 (Figure  4.2 A-D), reaching a total number of cells over  1x109   at 
P5. This number of passages could be further lowered to reach this number of cells, which 
is well above what is commonly considered to be therapeutic dose - of at least 2 x 106 
MSCs/kg of body weight for infusion - by increasing the amount of Wharton’s Jelly 
fragments, since only a small part of each umbilical cord sample was processed and used. 
In terms of clinical applications, it is not possible to use of MSCs without previous ex vivo 
expansion, in order to achieve the necessary therapeutic dose42,91. Notably, the generation 
time did not increase significantly when cells reach P8, corresponding about 22 cumulative 
population doublings (Figure 4.2- A and C), which indicate that the WJs-MSCs isolated did 
not reach senescence until this number of duplications,  in agreement with literature that  
revealed  that  WJ-MSCs could be kept in proliferative conditions in vitro until 
approximately 33 cumulative population doublings (33.7 ± 2.1)96 before entering 
replicative senescence. The cells demonstrated also to be able to form colonies with similar 
frequency with no statistically significant differences at passages 2 and 8 (Figure 4.3), which 
indicates that the cells were proliferative, maintaining stemness for at least 8 passages.  
The efficiency of CFU-F of these cells at P2 and P8 was 45 ± 6.96 and 28 ± 3.43 respectively, 
which is consistent with the efficiency described in the literature by Hou et al. for these 
cells, 35.2 ± 2.69.   
The immunophenotypic  characterization of WJ-MSCs , together with  proliferation 
kinetics, added to the fact that cells were adherent to plastic, displayed fibroblast-like 
morphology and presented CFU-F capacity , validated their genuine MSC identity. The 
immunophenotype  analysis showed that the cells were positive for CD13, CD73, CD90 and 
CD105 (Figure 4.4 A - D) and lacked of expression of CD34 and CD45 (Figures 4.4 E ,F) as 
expected10.     
MSCs secrete several soluble factors, such as cytokines, growth factors and 
extracellular matrix molecules that play and important role in the regulation of 
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haematopoiesis and in immune and inflammatory response. These soluble factors have 
been proposed as one of the key of MSCs’ therapeutic versatility94,97. The results obtained 
by multiplex cytokine analysis revealed a tendency in both conditions analyzed - WJ-MSCs 
alone and WJ-MSCs co-cultured with MNCs cells without any stimulation in vitro - showing 
that WJ-MSCs cultured on 1:40 PDMS substrates had higher secretion of cytokines than 
those maintained on tissue culture plates (TCP).  WJ-MSCs secretory profile demonstrated 
significant higher secretion for IL-2, IL-4 and IL-6 comparing with TCP (Fig.4.5 and 4.6). The 
secretion of IL-6 and IL-8 observed, corroborates with previous studies reporting  this 
feature53,94. IL-8 is associated with innate immune responses during which it induces 
chemotaxis and IL-6 is a multifunctional cytokine that plays a central role in host defense 
due to its wide range of immune and hematopoietic activities. IL-4 and IL-2 secretion by 
MSCs were significant higher in WJ-MSCs cultured on 1:40 PDMS comparing with TCP. To 
our best knowledge, this observation has not yet been described in the literature, which 
might be due to the sensitive analysis performed which allows detection of these cytokines. 
Furthermore, to confirm IL-4 secretion by WJ-MSCs an mRNA expression analysis could be 
done.  IL-4 has an important role in regulating antibody production, haematopoiesis and 
inflammation, and the development of effector T-cell response.  
 When WJ-MSCs cultured on different substrates were co-cultured with MNCs a 
tendency was observed, WJ-MSCs previously cultured from 1:40 PDMS substrates co-
cultured with MNCs showed a tendency for increased secretion of several cytokines, in 
particularly a significant increase for IL-4 and IL-8 (Fig.4.7 and 4.8) when compared with co-
cultures of MNCs with MSCs kept on TCP.  
Additionally, as shown in figure 4.9, by comparing the concentration of cytokines 
secreted (normalized to the total number of cells), between MNCs alone and MNCs in co-
culture with WJ-MSCs, there was notable increase of all cytokines under analysis, with the 
exception for TNF-α. Statistically significant differences were observed for the 
concentration of IL-2, IL-4, IL-10 and IFN-γ present in the co-culture medium when WJ-MSCs 
were previously cultured on 1:40 PDMS (but not TCP) when compared with MNCs alone 
(Figure 4.9). These results suggest that the cytokine context of MNCs alone or in co-culture 
with MSCs previously cultured on 1:40 PDMS substrates is significantly different. Although 
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these experiments did not allow to identify subpopulations of cells (MSCs or MNCs) 
responsible for these differences, we may speculate (based on existing literature) that the 
increase observed might be due to the presence of MNCs that could be enhancing the 
secretion of the cytokines analysed.   
MSCs have an immunomodulatory capability and low immunogenicity which make 
them attractive for the clinical applications, namely for immune system disorders 
candidates for MSCs cell therapy like of Graft versus host disease, autoimmune disorders, 
among others. These pathologies are heterogeneous in what concerns to the distribution 
of T cells among their functional compartments. MSCs are able to inhibit T and B cells and 
natural killer (NK) cells, induce of regulatory T cells and inhibition of antigen presenting 
cells. MSCs immunomodulation seems to be mediated by the secretion of soluble factors 
and direct contact, creating an immunosuppressive microenvironment.  
CD4+ and CD8+ T cells have different functional compartments naturally occurring in 
the peripheral blood of healthy individuals. The central memory preferentially mounts 
recall responses to antigens. Even though these cells lack immediate effector functions, 
they rapidly proliferate and differentiate into effector T cells. Effector memory cells 
provides immediate protection upon antigen challenge through the rapid production of 
effector cytokines. The functional compartments were identified within CD4+ and CD8+ T 
cells populations by flow cytometry, based on their differential expression of CD45RA and 
CD27 and the production of pro-inflammatory cytokines - IL-2 and TNF-α - was evaluated 
within each cell functional compartment.  
Our preliminary results showed that, in co-culture with MNCs (stimulated with PMA 
+ ionomycin), WJ-MSCs induce a generalized decrease of the percentage of CD4+ and CD8+ 
T cells expressing IL-2 and TNF-α (Figure 4.10). These observations are in agreement with 
previous studies reporting that MSCs have immunosuppressive abilities and induce a  
decrease of the percentage of T cells producing these cytokines  in vitro experiments and 
in vivo (at the mRNA level)35,98. Analysing within each T cell functional compartment, it 
seems that WJ-MSCs previously cultured on distinct substrates induce different levels of T 
cell inhibition. MSCs obtained from PDMS substrates and then co-cultured with MNCs 
revealed a higher tendency to downregulate the percentage of IL-2 expressing CD4+ and 
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CD8+ T cells in all functional compartments as compared with MSCs cultured on TCP, except 
for naïve functional compartment CD4+ T cells compared with TCP. This decrease is more 
pronounced among CD4+ T cells, where the effect was the same (Figure 4.10). This decrease 
was also more pronounced among CD4+ than CD8+ cells (Fig.4.10).  WJ-MSCs cultured on 
1:40 PDMS, showed a 97% percentage of inhibition in CM and EM memory CD4+ T cells.   
Concerning TNF-α expressing T cells, WJ-MSCs induced a decrease of the 
percentage of CD4+ and CD8+ T cells expressing this cytokine in all functional compartments 
of both cell types (figure 4.11). In contrast with what was observed for IL-2, MSCs obtained 
from TCP or PDMS substrates seem to produce a similar immunosuppressive effect in terms 
of TNF-α expression. These observations suggest that distinct mechanism may govern the 
modulation of IL-2 and TNF-α positive T cells by MSCs. Overall, our results suggest that 
MSCs pre-cultured on 1:10 or 1:40 PDMS present an increased immunosuppressive ability 
towards CD4+ and CD8+ T cells, which is a novel and important observation in the field. 
Further studies must be performed in order to validate these results and eventually assess 
the relevance of these observations using an in vivo model.  
Several in vitro studies have shown that the immunosuppressive effect of MSCs is 
sustained in  trans-well systems, suggesting that soluble factors are responsible for such 
inhibition, while others studies claimed that a direct cell contact  is required, which may be 
due to the use of different systems  by the individual research groups35,99. In our 
experimental setup, the preliminary results obtained from WJ-MSCs conditioned medium 
from different substrates co-cultured with MNC (stimulated with PMA + ionomycin) did not 
showed a decrease in the percentage of IL-2 produced by CD4+ and CD8+ T cells (Figure 
4.12). Concerning to TNF-α, a very slight decreased was observed in all the functional 
compartments (except for naïve compartment) of both CD4+ and CD8+ T cells in terms of 
percentage and amount of protein (MFI) per cells (Figure 4.13). These preliminary results 
could indicated that a cell-cell contact is important and needed for MSCs 
immunosuppression, since the conditioned medium seemed to induce only a partial 
suppression of T cells as observed by a decreased expression of TNF-α, but not IL-2. Further 
experiments need to be done to elucidate this aspect, namely by performing assays directly 
comparing the effect between MSC-conditioned medium – in which there was no 
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communication between MSCs and MNCs – and the trans-well system setup, in which 
soluble factors are allowed to pass and establish communication between the distinct cell 
types. In future studies will also be interesting to evaluate mRNA expression in MSCs and 
purified CD4+ and CD8+ T cells.  
The preliminary results obtained with WJ-MSCs cultured on distinct substrates and 
then co-cultured with MNCS in vitro stimulated with LPS + IFN-γ did not revealed 
differences concerning the producing of TNF-α when comparing between WJ-MSCs 
obtained from different substrates (Figure 4.14 and 4.16). The same was observed when 
using only conditioned medium obtained from MSCs cultured on the distinct substrates 
(Figures 4.15 and 4.16).   
Taking together, the results obtained in this study suggest that elements related to 
mechanotransduction – namely substrate stiffness and ECM-protein composition – seem 
to influence the profile of cytokines secreted by WJ-MSCs, as well as their 
immunomodulatory ability towards CD4+ and CD8+ T cells.  
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6. Conclusion 
 
 Our results reveals that secretory profile of WJ-MSCs cultured on distinct substrates 
-  which include differences at the level of stiffness and ECM-protein composition – is 
modulated by those biophysical and biochemical elements, leading to a differential 
expression profile of distinct cytokines. This might have important implications in what 
concerns the therapeutic efficacy and therapeutic targets of MSCs as an emerging cell 
therapy. Our preliminary results also indicate that WJ-MSCs cultured on distinct substrates 
seems to possess different inhibitory patterns towards T cells, among the several T cell 
functional compartments, which may impact the outcome of MSCs cellular therapy. 
Overall, our results suggest that the protocols used for MSC expansion may be tuned 
according to the desired therapeutic application, both at the level of the secretory profile 
and immunomodulatory approaches. Understanding the impact of micro-environmental 
cues on WJ-MSCs, such as substrate stiffness and ECM protein composition, is therefore 
important to maximise their therapeutic effects.  
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